Eva Kontsekova
Overview
Explore the profile of Eva Kontsekova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kovacech B, Cullen N, Novak P, Hanes J, Kontsekova E, Katina S, et al.
Alzheimers Res Ther
. 2024 Nov;
16(1):254.
PMID: 39580468
Background: The spread of tau pathology closely correlates with the disease course and cognitive decline in Alzheimer's disease (AD). Tau-targeting immunotherapies are being developed to stop the spread of tau...
2.
Cullen N, Novak P, Tosun D, Kovacech B, Hanes J, Kontsekova E, et al.
EBioMedicine
. 2023 Dec;
99:104923.
PMID: 38101301
Background: Tau pathology correlates with and predicts clinical decline in Alzheimer's disease. Approved tau-targeted therapies are not available. Methods: ADAMANT, a 24-month randomised, placebo-controlled, parallel-group, double-blinded, multicenter, Phase 2 clinical...
3.
Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, et al.
Nat Aging
. 2023 Apr;
1(6):521-534.
PMID: 37117834
Alzheimer's disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter...
4.
Erickson M, Logsdon A, Rhea E, Hansen K, Holden S, Banks W, et al.
Brain Behav Immun
. 2023 Jan;
109:251-268.
PMID: 36682515
COVID-19 and especially Long COVID are associated with severe CNS symptoms and may place persons at risk to develop long-term cognitive impairments. Here, we show that two non-infective models of...
5.
Kovacech B, Fialova L, Filipcik P, Skrabana R, Zilkova M, Paulenka-Ivanovova N, et al.
EBioMedicine
. 2022 Jan;
76:103818.
PMID: 35078012
Background: The emergence of new SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) that harbor mutations in the viral S protein raised concern about activity...
6.
Palova D, Csokova N, Markova K, Kontsekova E, Kovacech B, Zilkova M
Gen Physiol Biophys
. 2021 Dec;
40(6):463-478.
PMID: 34897021
Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized by progressive memory decline, histopathological lesions such as amyloid β plaques and neurofibrillary tangles, and neuroinflammation driven by glial cells. Microglia,...
7.
Hudakova N, Hricikova S, Kulkarni A, Bhide M, Kontsekova E, Cizkova D
Pathogens
. 2021 Jun;
10(6).
PMID: 34064300
Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild...
8.
Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, et al.
Neurology
. 2020 Sep;
95(22):e3026-e3035.
PMID: 32973122
Objective: To investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls. Methods: We...
9.
Zilkova M, Nolle A, Kovacech B, Kontsekova E, Weisova P, Filipcik P, et al.
Acta Neuropathol Commun
. 2020 May;
8(1):74.
PMID: 32471486
Immunotherapies targeting pathological tau have recently emerged as a promising approach for treatment of neurodegenerative disorders. We have previously showed that the mouse antibody DC8E8 discriminates between healthy and pathological...
10.
Weisova P, Cehlar O, Skrabana R, Zilkova M, Filipcik P, Kovacech B, et al.
Acta Neuropathol Commun
. 2019 Aug;
7(1):129.
PMID: 31391090
Pathologically altered tau protein is a common denominator of neurodegenerative disorders including Alzheimer's disease (AD) and other tauopathies. Therefore, promising immunotherapeutic approaches target and eliminate extracellular pathogenic tau species, which...